Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

valuating afatinib head-to-head versus gefitinib as a first-line treatment in EGFR M+ NSCLC patients.  Patient recruitment for this trial has recently initiated.
  • LUX-Lung 8, a Phase III trial evaluating afatinib head-to-head versus erlotinib in second-line treatment of squamous cell carcinoma of the lung.  Patient recruitment for this trial has recently initiated.
  • For more information on these trials, please visit www.clinicaltrials.gov

    About Boehringer Ingelheim in OncologyBuilding on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.

    The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition.  Afatinib is an investigational orally-administered irreversible inhibitor of the ErbB family of receptor tyrosine kinases, which is currently in phase III clinical development in advanced NSCLC, head and neck cancer, and breast cancer.  Nintedanib (BIBF 1120) is an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis and is currently in phase III clinical development in NSCLC and ovarian cancer.  Volasertib is an investigational inhibitor of polo-like kinase that is currently being investigated in early phase trials.  Boehringer Ingelheim's oncolo
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
    4. Boehringer Ingelheim Unveils Diabetes Pipeline
    5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
    6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
    7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
    8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
    9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
    10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
    11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
    (Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 The Brandeis ... Los Angeles a premier and affordable laser tattoo ... treatment special. Dr. Brandeis, focus is in providing high quality cosmetic ... to all patients. " Southern California ...
    (Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ergonomically ... with Hitachi Koki of Japan ... North America . NuAire will utilize its network of ... Canada to offer assistance in application use, ...
    Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
    ... 1, 2011 Every year thousands of children are hospitalized ... for them. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share ... by colorful pills that look like candy. ... how you can prevent harm by locking your medicine up. ...
    ... N.J., Nov. 1, 2011 Quest Diagnostics Incorporated (NYSE: ... diagnostic testing, information and services, today announced the CE ... & RSV Direct test on the 3M™ Integrated Cycler. ... uses a proprietary technique to eliminate nucleic-acid sample extraction, ...
    Cached Medicine Technology:Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 2Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 3
    (Date:4/23/2014)... WEST LAFAYETTE, Ind. - Purdue University researchers have developed ... a living cell by using tiny gold particles with ... Irudayaraj, professor of agricultural and biological engineering, used gold ... material known as BRCA1 messenger RNA splice variants, which ... The number of these mRNA splice variants in a ...
    (Date:4/23/2014)... which patients might suffer potentially fatal side-effects from a ... brain scans using pattern recognition software similar to that ... developed by researchers at Imperial College London. Results of ... used the software are published in the journal ... million people each year worldwide. Ischemic strokes are the ...
    (Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
    (Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
    (Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
    Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
    ... 3 Yesterday in a historical,and unprecedented move, ... for House Bill 1150 to mandate commercial,insurance companies ... The,bill, introduced by House Speaker Dennis M. O,Brien, ... autism-related treatment for,individuals less than 21 years old., ...
    ... 3 Mergent, Inc., administrator for the,HealthShares(TM) Indexes, ... Exchange Traded Funds, today announced the following,change effective ... 9, 2008: ISTA,Pharmaceuticals (Nasdaq: ISTA ) will ... Ophthalmology Index. Jerini AG is being,acquired by Shire ...
    ... Enterprises of,Shijiazhuang, China, the world,s largest manufacturer of vinyl ... notified Medline,Industries, Inc., and other U.S. customers that they ... unable to meet their normal,agreements to customers. Hong Ray ... to supply will have a cost impact on the ...
    ... Details Support for Community Organizations, SOUTH PORTLAND, ... Shield donated more than $1.4 million to community ... charitable,activities are detailed in the recently released Maine ... found online at, http://www.anthem.com/maine/communityreport ., "All associates ...
    ... Triple-S,Management Corporation (NYSE: GTS ) today announced that ... quarter ended June 30, 2008,before the market opens on ... Officer, and Juan-Jose Roman, Finance Vice President,and Chief Financial ... and the outlook for the company at 10:00 a.m. ...
    ... Ro to Promote Circle of Promise ... #401, DALLAS, July 3 , WHAT: Circle of ... Brock (Dr. Ro) will bring the fight against breast cancer to ... their view on breast cancer in the ...
    Cached Medicine News:Health News:Pennsylvania Tells Autism Speaks to Stop Talking 2Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Ophthalmology Index 2Health News:Medline Receives Force Majeure Notice From Hong Ray Enterprises 2Health News:Anthem Blue Cross and Blue Shield Issues Community Report for 2007 2Health News:Triple-S Management Corporation Schedules Second-Quarter Earnings Release and Webcast 2Health News:Susan G. Komen for the Cure(R)'s Circle of Promise to Mobilize African American Women Against Breast Cancer at 2008 Music Festival 2
    ... is a multi-tasking vacuum source and solvent ... vapor trap and a maintenance-free, oil-free vacuum ... easy-to-use, wide-mouth glass condensation flask collects all ... easy disposal. The UVS400 provides an ideal ...
    ... Combines BchiVac V-500 with Vacuum Controller ... Electronic switching mechanism turns V-500 on and off ... Compact Housing Model V-500 is a powerful ... applications. Applications Ideally suited for use ...
    ... membrane vacuum pump designed to handle most vacuum ... use with up to two rotary evaporators ... ovens, concentrators, gel dryers, and filtration apparatuses ... to chemicals and heat load Corrosion-resistant ...
    ... Universal Vacuum Source is a combination instrument bringing ... 4-headed, Oil-free Vacuum Pump. It is designed to ... abuse., Combines a Refrigerated Cold Trap ... eliminating extra tubing connections. , ...
    Medicine Products: